U.S. Telecom Services and Carriers Stock News

Jazz Pharmaceuticals (JAZZ) has moved back into focus after a cluster of updates on its sleep and oncology portfolios, including 21 planned Xywav data presentations at SLEEP 2026 and recently published Phase 3 Ziihera results. See our latest analysis for Jazz Pharmaceuticals. Recent updates around Xywav and Ziihera, together with quarterly results that exceeded expectations, have arrived against a backdrop of strong momentum. A 90 day share price return of 28.68% and a 1 year total...

Recent move in Impinj (PI) stock Impinj (PI) has drawn investor attention after a recent pullback, with the stock down 11.2% over the past day and 20.9% over the past month, despite a 22.4% gain over the past 3 months. That mix of shorter term weakness and recent quarter strength is prompting closer scrutiny of the company’s US$3.7b valuation, its RAIN RFID focused business model, and the current gap between share price and fundamental performance. See our latest analysis for Impinj. With the...

We wouldn't blame NovoCure Limited ( NASDAQ:NVCR ) shareholders if they were a little worried about the fact that Frank...

Recent debate around Tapestry (TPR) has intensified as differing valuation views, insider share sales and a softer backdrop for luxury stocks converge. This has prompted investors to reassess the company’s growth outlook and profit profile. See our latest analysis for Tapestry. Tapestry’s share price has pulled back over the past week, with a 7 day share price return of 3.68% and a 90 day share price return of 3.71% decline. However, the 1 year total shareholder return of 79.74% and 5 year...

CEO commentary puts Karooooo (KARO) in focus Fresh comments from Karooooo (KARO) CEO Zak Calisto on accelerating subscription revenue growth, strong free cash flow and international expansion have put the stock back on many investors’ watchlists. Together with upbeat analyst views on earnings estimate revisions and reported fundamentals, this recent commentary is shaping how investors assess Karooooo’s growth profile and risk balance today. See our latest analysis for Karooooo. Karooooo’s...

In early June 2026, CRISPR Therapeutics AG filed a shelf registration for up to US$969.16 million in common shares linked to its employee stock plans, shortly after shareholders approved amendments to the company’s articles of association at the annual meeting. Coming on the heels of high-profile conference presentations and growing attention to its Casgevy launch and cardiovascular gene-editing pipeline, these corporate moves highlight how CRISPR Therapeutics is building financial and...

Lamb Weston Holdings (LW) plans to close its Broekhuizenvorst, Netherlands production facility, affecting about 110 employees, as part of its Focus to Win supply chain realignment in response to current market conditions. See our latest analysis for Lamb Weston Holdings. The Broekhuizenvorst closure headlines come after a weak run for the stock, with the latest share price at US$42.12 and the 1 year total shareholder return down 22.08%, while 3 and 5 year total shareholder returns also show...

In late May and early June 2026, Abbott highlighted new data showing rising, often-missed diabetic ketoacidosis cases and secured CE Mark approval in Europe for Libre Duo and Libre Duo 10 Day, its first-of-its-kind dual glucose‑ketone continuous monitoring systems, while awaiting U.S. FDA clearance. The combination of alarming national trends in DKA-related hospitalizations and Abbott’s dual-analyte sensor positions the company to address a critical gap in diabetes care. We’ll now examine...

Driven Brands Holdings Inc. previously received a Nasdaq notice after delaying its First Quarter 2026 10-Q filing, following an earlier restatement-driven delay to its 2025 10-K, and now has until July 31, 2026 to submit a compliance plan and up to November 25, 2026 to regain full listing compliance. While the notice has no immediate effect on the Nasdaq listing, the filing delay and prior restatement focus attention on Driven Brands’ financial reporting controls and timeline for returning...

Pharvaris (PHVS) is back in focus after announcing that eight deucrictibant abstracts, including Phase 3 and long term safety data, have been accepted for presentation at the 2026 European Academy of Allergy and Clinical Immunology Congress. See our latest analysis for Pharvaris. At a share price of US$31.09, Pharvaris has seen a 17.4% year to date share price return and an 85.3% total shareholder return over one year. The 1 day move was a modest pullback that contrasts with stronger 90 day...

Capricor Therapeutics recently cleared a key hurdle for its lead Duchenne muscular dystrophy therapy Deramiocel, completing an FDA Pre-License Inspection at its San Diego GMP facility and securing a Prescription Drug User Fee Act (PDUFA) decision date in August for its Biologics License Application. This combination of regulatory progress, manufacturing readiness, and cash runway reportedly extending through the fourth quarter of 2027 gives Capricor unusual visibility on its ability to fund...

In its first full quarter since combining with MRC Global, DNOW reported strong revenue growth but weaker profitability, citing ERP transition costs, lower U.S. volumes, and integration efforts that included raising expected 2026 cost synergies to about US$30 million and acquiring Edge Controls to broaden its automation capabilities. At the same time, Rosen Law Firm began investigating potential securities claims over allegedly misleading past disclosures, adding a legal overhang just as...

Ventas stock performance snapshot Ventas (VTR) has drawn investor attention after a mixed recent performance, with the stock up 3.7% in the past day but down over the past week, month and past 3 months. Over the past year, Ventas has delivered a 32.4% total return and is up 6.1% year to date. This gives investors a reference point against its longer term 3 year and 5 year total returns. See our latest analysis for Ventas. The recent 1 day share price return of 3.7% to US$82.02 comes after...

GPGI (GPGI) is back in focus after shareholders approved a move to shift the company’s corporate domicile from Delaware to Nevada. This governance change will be formally detailed in an upcoming Form 8-K filing. See our latest analysis for GPGI. The governance shift to Nevada comes at a time when the stock has been under pressure, with the 30 day share price return down 14.34% and the 90 day share price return down 42.42%, even though the 3 year total shareholder return sits at 112.30%. This...

Geopolitical shocks in the Gulf, higher oil prices, and disrupted trade routes are reshaping the risk and opportunity profile for energy related stocks. For investors, this kind of tension can quickly change which companies are better placed to handle supply risks, cost pressures, and swings in demand. This article focuses on three large oil and gas producers from a curated screener that targets size and financial strength. Each stock is exposed to the current news backdrop in different ways,...

Earlier this week, Solidion Technology Inc. announced patented breakthroughs in lithium metal and extreme-climate battery platforms tailored for satellites, Low Earth Orbit AI data centers, crewed spacecraft, and future lunar infrastructure, underpinned by more than 385 patents. A distinctive aspect of these announcements is Solidion’s focus on graphene-enabled, ultra-wide-temperature batteries and domestic graphite production, directly addressing both harsh space conditions and U.S...

In early June 2026, Comstock Resources reported first-quarter 2026 adjusted earnings of US$0.15 per share, missing estimates as severe weather cut production volumes, even though total revenue rose on stronger natural gas price realizations and higher gas services income. At the same time, Comstock highlighted a long-term opportunity to supply natural gas to a planned 5.2 GW power generation hub in Texas by 2031, pointing to a potential new demand center closely tied to its Western...

Exelon (EXC) is back on many investors’ screens after a recent move in the share price, with the stock last closing at $45.75 and showing mixed returns over the past year. See our latest analysis for Exelon. Recent trading reflects this mixed picture, with a 2.51% 1 day share price return and a 4.19% 30 day share price return, in contrast with a 6.90% decline over 90 days. Total shareholder returns of 11.22% over 1 year and 63.14% over 5 years highlight how reinvested dividends have...

We'd be surprised if IRADIMED CORPORATION ( NASDAQ:IRMD ) shareholders haven't noticed that the Independent Director...

Investors may wish to note that the CEO, President & Director of Pulmonx Corporation , Glendon French, recently netted...

Some Lincoln National Corporation ( NYSE:LNC ) shareholders may be a little concerned to see that the Executive VP and...

Those following along with Erie Indemnity Company ( NASDAQ:ERIE ) will no doubt be intrigued by the recent purchase of...

We wouldn't blame The TJX Companies, Inc. ( NYSE:TJX ) shareholders if they were a little worried about the fact that...

WD-40 (WDFC) has drawn fresh attention after announcing a broad executive reshuffle, with current CFO Sara Hyzer set to lead the Americas division and several senior leaders moving into newly defined roles. See our latest analysis for WD-40. At a share price of $203.39, WD-40 has seen its short term share price momentum fade. The 90 day share price return is down 11.65%, while the 3 year total shareholder return is 11.89% and the 1 year total shareholder return is down 15.57%. This frames the...